Comorbidities and Healthcare Utilisation: Indicators for Improving COPD Diagnosis

NCT01655667 | Completed DMC

• 1 other identifier: 015/11
• Study Type: observational
• Target: 38,859
• Locations: 1 country
• Sites: 1

Brief Summary

To characterise and understand the current UK COPD population including demographics, active comorbidities and missed opportunities for COPD diagnosis in the years previous to diagnosis

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Diagnosis; Primary Care; Comorbidities; Healthcare utilisation

Study Arms (1)

Chronic Obstructive Pulmonary Disease

All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects aged 40 years or older, with an electronically coded diagnosis of COPD made between 1990 and 2009, a minimum of three years continuous practice data including two years prior to and one year post diagnosis to ensure patients recieved COPD therapy post diagnosis (defined as two or more prescriptions for COPD therapies in the 12 months post diagnosis year 1). COPD therapies included short- and long-acting bronchodilators, inhaled corticosteroids, theophylline and leukotriene receptor antagonists.

You may qualify if:

• Aged 40 years or older
• Electronically coded diagnosis of COPD made between 1990 and 2009
• A minimum of three years continuous practice data including two years prior to and one year post diagnosis to ensure patients recieved COPD therapy post diagnosis
• Recieved two or more prescriptions for COPD therapies in the 12 months post diagnosis year 1.

You may not qualify if:

• Aged less than 40 years
• No diagnosis of COPD between 1990 and 2009
• Less than three years continuous practice data including two years prior to and one year post diagnosis
• Less than two prescriptions for COPD therapies in the 12 months post diagnosis year 1.

Sponsors & Collaborators

• Research in Real-Life Ltd: lead
• Department of Health, United Kingdom: collaborator

Study Sites (1)

Research in Real Life Ltd

Cambridge, Cambridgeshire, CB24 3BA, United Kingdom

Location

Related Publications (1)

• Jones RC, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DM, Winter R, Hill S, Kearney M, Holton K, Moger A, Freeman D, Chisholm A, Bateman ED; Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014 Apr;2(4):267-76. doi: 10.1016/S2213-2600(14)70008-6. Epub 2014 Feb 13.

  PMID: 24717623 DERIVED

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Disease

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• David B Price, MD

  Research in Real-Life Ltd

  PRINCIPAL INVESTIGATOR

• Dermot Ryan, MBBS

  University of Edinburgh

  STUDY DIRECTOR

• Rupert Jones, MBBS

  Peninsula College of Medinicne and Dentistry

  STUDY DIRECTOR

• Eric Bateman, MD

  University of Cape Town

  STUDY DIRECTOR

• Matt Kearney, MPH

  Department of Health, United Kingdom

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor David Price

Study Record Dates

• First Submitted: July 31, 2012
• First Posted: August 2, 2012
• Study Start: December 1, 2010
• Primary Completion: February 1, 2011
• Study Completion: June 1, 2012
• Last Updated: August 2, 2012

Record last verified: 2012-08

Locations

GB (1)